Overview of antidepressant treatment of bipolar depression

International Journal of Neuropsychopharmacology

Volumn 16, Issue 7, 2013, Pages 1673-1685

  Vázquez, Gustavo H ^a,b   Tondo, Leonardo ^a,c,d   Undurraga, Juan ^a,e   Baldessarini, Ross J ^a,c  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF PALERMO   (Argentina)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Lucio Bini Mood Disorder Center   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

bipolar disorders; depression; Key words Antidepressants; treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM SALT; LURASIDONE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PALIPERIDONE; PAROXETINE; PLACEBO; PREGABALIN; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; TRANYLCYPROMINE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE;

BIPOLAR DEPRESSION; BRAIN DEPTH STIMULATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPOMANIA; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MOOD CHANGE; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DATABASES, FACTUAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84880537570     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000023     Document Type: Review

References (134)

1. Agosti V, Stewart JW (2007) Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int Clin Psychopharmacol 22:309-311.
2. Altshuler L, Suppes T, Black D, Nolen WA, Keck Jr. PE, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, Leverich G, Denicoff K, Luckenbaugh D, Post R (2003) Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at one-year follow-up. Am J Psychiatry 160:1252-1262.
3. Amit BH, Weizman A (2012) Antidepressant treatment for acute bipolar depression: An update. Depress Res Treat. Advance online publication. doi:10.1155/2012/684725.
4. Amsterdam JD, Shults J (2005) Comparison of fluoxetine, olanzapine, and the combination of fluoxetine and olanzapine in initial therapy of bipolar type I and type II major depression: lack of manic induction. J Affect Disord 87:121-130.
5. Amsterdam JD, Shults J (2008) Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: Randomized open-label study. J Clin Psychopharmacol 28:171-181.
6. Angst F, Stassen HH, Clayton PJ, Angst J (2002) Mortality of patients with mood disorders : Follow up of 34-38 years. J Affect Disord 68:167-181.
7. Angst J, Azorin JM, Bowden C, Perugi G, Vieta E, Gamma A, Young AH (2011) Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode. Arch Gen Psychiatry 68:791-799.
8. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L (2008) Psychotropic medications for patients with bipolar disorder in the United States : Polytherapy and adherence. Psychiatr Serv 59:1175-1183.
9. Baldessarini RJ (2013) Chemotherapy in psychiatry, 3rd edn. New York: Springer Press.
10. Baldessarini RJ, Faedda GL, Hennen J (2005) Risk of mania with serotonin reuptake inhibitors vs. tricyclic antidepressants in children, adolescents and young adults. Arch Pediatr Adolesc Med 159:298-299.
11. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J (2007a) Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv 58:85-91.
12. Baldessarini RJ, Salvatore P, Khalsa H-MK, Gebre-Medhin P, Imaz H, Gonza'lez-Pinto A, Perez J, Cruz N, Maggini C, Tohen M (2010a) Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord 12:264-270.
13. Baldessarini RJ, Salvatore P, Khalsa H-MK, Tohen M (2010b) Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder. J Affect Disord 126:299-302.
14. Baldessarini RJ, Tondo L, Ghiani C, Lepri B (2010c) Discontinuation rate vs. recurrence risk following long-term antidepressant treatment in major depressive disorder patients. Am J Psychiatry 167:934-941.
15. Baldessarini RJ, Undurraga J, Va'zquez GH, Tondo L, Salvatore P, Ha K, Khalsa H-MK, Lepri B, Ha TH, Chang JS, Tohen M, Vieta E (2012) Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand 125:293-302.
16. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL (2010d) Bipolar depression: overview and commentary. Harv Rev Psychiatry 18:143-157.
17. Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler LL, Mandelkern MA, Bramen J, Voytek B, Woods R, Mazziotta JC, Whybrow PC (2005a) Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry 10:456-469.
18. Bauer MS, Altshuler L, Evans DR, Beresford T, Williford WO, Hauger R (2005b) Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord 85:301-315.
19. Bauer MS, Ritter P, Brunze H, Pfennig A (2012) Treatment options for acute depression in bipolar disorder. Bipolar Disord 14 (Suppl. 2) :37-50.
20. Biernacka JM, McElroy SL, Crow S, Sharp A, Benitez J, Veldic M, Kung S, Cunningham JM, Post RM, Mrazek D, Frye MA (2012) Pharmacogenomics of antidepressant induced mania: Review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord 136:e21-e29.
21. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M (1993) Double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 88:434-439.
22. Brown EB, McElroy SL, Keck Jr. PE, Deldar A, Adams DH, Tohen M, Williamson DJ (2006) Seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 67:1025-1033.
23. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA (2008) Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 10:323-333.
24. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, FryeMA (2010) Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder : Randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 71:1363-1370.
25. Calabrese JR, Muzina DJ, Kemp DE, Sachs GS, Frye MA, Thompson TR, Klingman D, Reed ML, Hirschfeld RMA (2006) Predictors of bipolar disorder risk among patients currently treated for major depression. Med Gen Med 8:38.
26. Cazard R, Ferreri F (2012) Bipolar disorders and comorbid anxiety : P rognostic impact and therapeutic challenges (French). Encephale. Advance online publication. Retrieved 15 June 2012. doi : 10.1016/j.encep.2012.04.005.
27. Centorrino F, Masters GA, Talamo A, Baldessarini RJ, O? ngu?r D (2012) Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol 27:521-526.
28. Cohn JB, Collins G, Ashbrook E, Wernicke JF (1989) Combination of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4 :313-322.
29. Correa R, Akiskal H, Gilmer W, Niereneberg AA, Trivedi M, Zisook S (2010) Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord 127:10-18.
30. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E (2010) Efficacy of modern antipsychotics in placebocontrolled trials in bipolar depression: Meta-analysis. Int J Neuropsychopharmacol 13:5-14.
31. De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, Souery D, Claes S (2012) Second generation antipsychotics in the treatment of bipolar depression: systematic review and meta-analysis. J Psychopharmacol 26:603-617.
32. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Mo? ller H-J, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S (2011) Physical illness in patients with severe mental disorders : P revalence, impact of medications and disparities in health care. World Psychiatry 10:52-77.
33. Dierckx B, Heijnen WT, van den Broek WW, Birkenha?ger TK (2012) Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: Meta-analysis. Bipolar Disord 14:146-150.
34. Fountoulakis KN (2010) Update of evidence-based treatment of bipolar depression: Where do we stand? Curr Opin Psychiatry 23:19-24.
35. Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, Versiani M, Tandon R, Mo? ller H-J, Vieta E (2012) Efficacy of pharmacotherapy in bipolar disorder : Report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262 (Suppl. 1) :1-48.
36. Frye MA, Grunze H, Suppes T, McElroy SL, Keck Jr. PE, Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwang S, Mintz J, Post RM (2007) Placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 164:1242-1249.
37. Frye MA, Ha K, Kanba S, Kato T, McElroy SL, O? zerdem A, Va'zquez GH, Vieta E (2011) International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry 72:1295-1310.
38. Frye MA, Helleman G, McElroy SL, Altshuler LL, Black DO, Keck Jr. PE, Nolen WA, Kupka R, Leverich GS, Grunze H, Mintz J, Post RM, Suppes T (2009) Correlates of treatmentemergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 166:164-172.
39. George MS, Taylor JJ, Short EB (2013) The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry 26:13-18.
40. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK (2003) Antidepressants in bipolar disorder : The case for caution. Bipolar Disord 5 :421-433.
41. Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs GS, Goodwin FK, Baldessarini RJ (2010) Antidepressant discontinuation in bipolar depression: systematic treatment enhancement program for bipolar disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71:372-380.
42. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ (2004) Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 161:163-165.
43. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ (2008) Long-term antidepressant treatment in bipolar disorder : Meta-analyses of benefits and risks. Acta Psychiatr Scand 118:347-356.
44. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: systematic review of randomized, controlled trials. Am J Psychiatry 161:1537-1547.
45. Goldberg JF, Perlis RH, Ghaemi SN, Calabrese JR, Bowden CL, Wisniewski S, Miklowitz DJ, Sachs GS, Thase ME (2007) Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: Findings from the STEP-BD. Am J Psychiatry 164:1348-1355.
46. Goodwin GM (2009) Evidence-based guidelines for treating bipolar disorder : Revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford) 23:346-388.
47. Grossman F, Potter WZ, Brown EA, Maislin G (1999) Double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord 56:237-243.
48. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Mo? ller H-J, Kasper S (2010) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update on treatment of acute bipolar depression. World J Biol Psychiatry 11:81-109.
49. Heeren O, Sanchez de Carmona M, Va'zquez GH, Cordoba R, Forero J, Madrid L, Lara D, Medina R, Meza L (2011) Psychotropic drug treatment preferences for Latin American bipolar disorder patients. Rev Psiquiatr Salud Ment 4:205-211.
50. Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910-916.
51. Howland RH (2012) Use of dopaminergic and stimulant drugs for the treatment of depression. J Pyschosoc Nurs Ment Health Serv 50:11-14.
52. Joffe RT, MacQueen GM, Marriott M, Young LT (2005) One-year outcome with antidepressant-treatment of bipolar depression. Acta Psychiatr Scand 112:105-109.
53. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) Long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:530-537.
54. Keck Jr. PE, Kessler RC, Ross R (2008) Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pract 14 (Suppl. 2) :31-38.
55. Keck Jr. PR, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye ME, Altshuler LL, Kupka R, Nolen WA, Leverish GS, Denicoff KD, Grunze H, Duan N, Post RM (2006) Double-blind, randomized, placebo-controlled trials of ethyleicosopentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60:1020-1022.
56. Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, Conigliaro J, Haas GL (2004) Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 6 :368-373.
57. Krishnan KRR (2005) Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 67:1-8.
58. Kupfer DJ (2005) Increasing medical burden in bipolar disorder. J Am Med Assoc 293:2528-2530.
59. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck Jr. PE, McElroy SL, Grunze H, Post RM (2007) Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9 :531-535.
60. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ (2012) Can bipolar disorder be viewed as a multisystem inflammatory disease? J Affect Disord 141:1-10.
61. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck Jr. PE, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM (2006) Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163:232-239.
62. Licht RW, Gijsman H, Nolen WA, Angst J (2008) Are antidepressants safe in the treatment of bipolar depression? Critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 118:337-346.
63. Lolich M, Va'zquez GH, Alvarez LM, Tamayo JM (2012) Psychosocial interventions in bipolar disorder : Review. Acta Esp Psiquiatr 40:84-92.
64. Lorenzo LS, Va'zquez GH, Zaratiegui RM, Tondo L, Baldessarini RJ (2012) Characteristics of bipolar disorder patients given antidepressants. Hum Psychopharmacol 27:486-491.
65. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D (2004) Age effects on antidepressantinduced manic conversion. Arch Pediatr Adolesc Med 158:773-780.
66. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH (2010) Double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163-174.
67. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, Kessler RC (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543-552.
68. Muzina DJ, Gao K, Kemp DE, Khalife S, Ganocy SJ, Chan PK, Serrano MB, Conroy CM, Calabrese JR (2011) Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: double-blind, randomized, placebocontrolled trial. J Clin Psychiatry 72:813-819.
69. National Institute for Health and Clinical Excellence (2006) Clinical guidelines: bipolar disorder, management in adults, children and adolescents in primary and secondary care. London: National Institute for Health and Clinical Excellence.
70. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD (2001) Double-blind, placebocontrolled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158:906-912.
71. Nivoli AMA, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonza'lez-Pinto A, Fountoulakis KN, Vieta E (2011) New treatment guidelines for acute bipolar depression: A systematic review. J Affect Disord 129:14-26.
72. Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, Suppes T, Keck Jr. PE, McElroy S, Grunze H, Mintz J, Post RM (2007) Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study. Acta Psychiatr Scand 115:360-365.
73. Novick DM, Swartz HA, Frank E (2010) Suicide attempts in bipolar I and bipolar II disorder : Review and meta-analysis of the evidence. Bipolar Disord 12:1-9.
74. O'Donovan C, Garnham JS, Hajek T, Alda M (2008) Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord 107:293-298.
75. O? sby U, Brandt L, Correia N, Ekbom A, Sparén P (2001) Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58:844-850.
76. Owen RT (2012) Glutamatergic approaches in major depressive disorder : Focus on ketamine, memantine and riluzole. Drugs Today 48:469-478.
77. Pacchiarotti I, Valentí M, Bonnin CM, Rosa AR, Murru A, Kotzalidis GD, Nivoli AMA, Sa'nchez-Moreno J, Vieta E, Colom F (2011a) Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol 21:362-369.
78. Pacchiarotti I, Valentí M, Colom F, Rosa AR, Nivoli AMA, Murru A, Sa'nchez-Moreno J, Vieta E (2011b) Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord 129:321-326.
79. Parker G, Brotchie H (2010) Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand 121:308-314.
80. Paykel ES, Abbott R, Morriss R, Hayhurst H, Scott J (2006) Subsyndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry 189:118-123.
81. Peet M (1994) Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164:549-550.
82. Perlis RH, Ostacher MJ, Goldberg JF, Miklowitz DJ, Friedman E, Calabrese J, Thase ME, Sachs GS (2010) Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 35:2545-2552.
83. Perlis RH, Uher R, Ostacher M, Goldberg JF, Trivedi MH, Rush AJ, Fava M (2011) Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 68:351-360.
84. Phelps J, Angst J, Katzow J, Sadler J (2008) Validity and utility of bipolar spectrum models. Bipolar Disord 10:179-193.
85. Pompili M, Tondo L, Baldessarini RJ (2005) Suicidal risk emerging during antidepressant treatment: Recognition and intervention. Clin Neuropsychiatry 2 :66-72.
86. Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ (2012) Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord 14:573-584.
87. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, Kitchen CM, Mintz J (2006) Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189:124-131.
88. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck Jr. PE, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA (2003a) Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 64:680-690.
89. Post RM, Leverich G, Altshuler L, Frye M, Suppes T, Keck Jr. PE, McElroy SL, Nolen W, Kupka R, Grunze H, Walden J, RoweM (2011) Differential clinical characteristics, medication usage, and treatment response of bipolar disorder patients in the US versus Netherlands and Germany. Int Clin Psychopharmacol 26:96-106.
90. Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck Jr. PE, Nolen WA, Rowe M, Kupka RW, Grunze H, Goodwin FK (2012) Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry 73:924-930.
91. Post RM, Leverich GS, Nolen WA, Kupka RW, Altshuler LL, Frye MA, Suppes T, McElroy S, Keck P, Grunze H, Walden J (2003b) Re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley foundation bipolar network. Bipolar Disord 5 :396-406.
92. Reinares M, Rosa AR, Franca C, Goikolea JM, Fountoulakis K, Siamouli M, Gonda X, Frangou S, Vieta E (2012) Systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacology 10:1-12.
93. Rihmer Z, Gonda X (2011) Antidepressant-resistant depression and antidepressant-associated suicidal behavior: Role of underlying bipolarity. Depress Res Treat. Advance online publication. doi:10.1155/2011/906462.
94. Rizvi SJ, Donovan M, Giacobbe P, Plancenza F, Rotzinger S, Kennedy SH (2011) Neurostimulation therapies for treatment resistant depression: Focus on vagus nerve stimulation and deep brain stimulation. Int Rev Psychiatry 23:424-436.
95. Rosa AR, Bonni'n CM, Va'zquez GH, Reinares M, Solé B, Tabare's- Seisdedos R, Balanzá-Marti'nez V, Gonza'lez-Pinto A, Sa'nchez- Moreno J, Vieta E (2010) Functional impairment in bipolar II disorder : Is it as disabling as bipolar I? J Affect Disord 127:71-76.
96. Roshanaei-Moghaddam B, Katon W (2009) Premature mortality from general medical illnesses among persons with bipolar disorder : Review. Psychiatr Serv 60:147-156.
97. Rybakowski JK (2012) Bipolarity and inadequate response to antidepressant drugs: Clinical and psychopharmacological perspective. J Affect Disord 136:e13-e19.
98. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF (1994) Double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55:391-393.
99. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. New Engl J Med 356:1711-1722.
100. Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z (2011) Levetiracetam in the management of bipolar depression: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72:744-750.
101. Sarris J, Mischoulon D, Schweitzer I (2011) Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder : systematic review of clinical trials. Bipolar Disord 13:454-465.
102. Schaffer A, Zuker P, Levitt A (2006) Randomized, double-blind pilot trial comparing lamotrigine versus citaloporam for the treatment of bipolar depression. J Affect Disord 96:95-99.
103. Sharma V, Khan M, Smith A (2005) Closer look at treatment resistant depression: Is it due to a bipolar diathesis? J Affect Disord 84:251-257.
104. Shelton RC, Stahl SM (2004) Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 65:1715-1719.
105. Sidor MM, MacQueen GM (2011) Antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. J Clin Psychiatry 72:156-167.
106. Sidor MM, MacQueen GM (2012) An update on antidepressant use in bipolar depression. Curr Psychiatry Rep 14:696-704.
107. Silverstone T (2001) Moclobemide vs. imipramine in bipolar depression: Multicenter double-blind clinical trial. Acta Psychiatr Scand 104:104-109.
108. Sussman M, Friedman M, Korn JR, Hassan M, Kim J, Menzin J (2012) The relationship between use of antidepressants and resource utilization among patients with manic or mixed bipolar disorder episodes : Findings from a managed care setting. J Affect Disord 138:425-432.
109. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R (2008) Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of two randomized, placebo-controlled studies. J Clin Psychopharmacol 28:13-20.
110. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez J-C (2012) Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 201:376-382.
111. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088.
112. Tondo L, Baldessarini RJ, Va'zquez GH, Lepri B, Visioli C (2012) Clinical responses to antidepressants among acutely depressed patients with bipolar-I, bipolar-II, or unipolar major affective disorder. Acta Psychiatr Scand 125:293-302.
113. Tondo L, Isacsson G, Baldessarini RJ (2003) Suicide in bipolar disorder : Risk and prevention. CNS Drugs 17:491-511.
114. Tondo L, Lepri B, Baldessarini RJ (2007) Suicidal risks among 2826 Sardinian major depressive disorder patients. Acta Psychiatr Scand 116:419-428.
115. Tondo L, Va'zquez G, Baldessarini RJ (2010) Mania associated with antidepressant treatment: Comprehensive meta-analytic review. Acta Psychiatr Scand 121:404-414.
116. Torrey EF, Davis JM (2012) Adjunct treatments for schizophrenia and bipolar disorder : What to try when you are out of ideas. Clin Schizophr Relat Psychoses 5 :208-216.
117. Undurraga J, Baldessarini RJ (2012) Randomized, placebocontrolled trials of antidepressants for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology 37:851-864.
118. Undurraga J, Baldessarini RJ, Valentí M, Pacchiarotti I, Tondo L, Va'zquez G, Vieta E (2012a) Bipolar depression: Clinical correlates of receiving antidepressants. J Affect Disord 139:89-93.
119. Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Vieta E (2012b) Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatry 73:778-782.
120. Undurraga J, Tondo L, Schalkwijk S, Vieta E, Baldessarini RJ (2012c) Re-analysis of the earliest controlled trials of imipramine. J Affect Disord. Advance online publication. doi : 10.1016/j.jad.2012.10.032.
121. Valentí M, Pacchiarotti I, Bonni'n CM, Rosa AR, Popovic D, Nivoli AMA, Goikolea JM, Murru A, Undurraga J, Colom F, Vieta E (2012) Risk factors for antidepressant-related switch to mania. J Clin Psychiatry 73:e271-276.
122. van der Loos MLM, Mulder P, Hartong EGTM, Blom MBJ, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E, Nolen WA (2010) Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand 122:246-254.
123. van der Loos MLM, Mulder PGH, Hartong EGTM, Blom MBJ, Vergouwen AC, de Keyzer HJUEM, Notten PJH, Luteijn ML, Timmermans MA, Vieta E, Nolen WA (2009) Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: Multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 70:223-231.
124. van Lieshout RJ, MacQueen GM (2010) Efficacy and acceptability of mood stabilizers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry 196:266-273.
125. Va'zquez G, Tondo L, Baldessarini RJ (2011) Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: Meta-analytic review. Pharmacopsychiatry 44:21-26.
126. Vieta E (2008) Antidepressants in bipolar depression. Acta Psychiatr Scand 118:335-336.
127. Vieta E, Martinez-Ara'n A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M (2002) A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 63:508-512.
128. Vo?hringer PA, Ghaemi SN (2011) Solving the antidepressant efficacy question: effect sizes in major depressive disorder. Clin Ther 33:B49-B61.
129. Wehr TA, Goodwin FK (1979) Rapid cycling in manicdepressives induced by tricyclic antidepressants. Arch Gen Psychiatry 36:555-559.
130. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW (1988) Rapid cycling affective disorder : Contributing factors and treatment responses in 51 patients. Am J Psychiatry 145:179-184.
131. Yatham LN, et al. (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder : Update 2013.
132. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Disord 11:225-255.
133. Young A, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I (2000) Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157:124-126.
134. Zarate Jr. CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: Randomized controlled add-on trial. Biol Psychiatry 71:939-946.